Randomized Trialhigh evidence
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)·July 4, 2026·PMID 42251856
Why it mattersFor patients on basal insulin with inadequate glycemic control, CagriSema offers a potent dual mechanism—GLP-1 receptor agonism plus amylin analog—that simultaneously improves HbA1c and promotes substantial weight loss without increasing hypoglycemia risk, addressing two major treatment challenges.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled